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Corticosteroid resistance is a major barrier to effective treatment in chronic obstructive 
pulmonary disease (COPD), and failure to suppress systemic inflammation in these 
patients may result in increased comorbidity. Although much of the research to date 
has focused on the role of macrophages and neutrophils involved in inflammation in the 
airways in COPD, recent evidence suggests that CD8+ T cells may be central regulators 
of the inflammatory network in this disease. CD8+ cytotoxic pro-inflammatory T cells 
have been shown to be increased in the peripheral blood and airways in patients with 
COPD, whereas smokers that have not progressed to COPD only show an increase in 
the lungs. Although the mechanisms underlying steroid resistance in these lymphocytes 
is largely unknown, new research has identified a role for cytotoxic pro-inflammatory 
CD8+ T-cells and CD8+ natural killer T-like (NKT-like) cells. Increased numbers of these 
cells and their significant loss of the co-stimulatory molecule CD28 have been shown in 
COPD, consistent with findings in the elderly and in clinical conditions involving chronic 
activation of the immune system. In COPD, these senescent cells expressed increased 
levels of the cytotoxic mediators, perforin and granzyme b, and the pro-inflammatory 
cytokines, IFNγ and TNFα. They also demonstrated increased cytotoxicity toward lung 
epithelial cells and importantly were resistant to immunosuppression by corticosteroids 
compared with their CD28+ counterparts. Further research has shown these cells evade 
the immunosuppressive effects of steroids via multiple mechanisms. This mini review will 
focus on cytotoxic pro-inflammatory CD8+CD28null NKT-like cells involved in COPD and 
novel approaches to reverse steroid resistance in these cells.
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CD8+ nATURAL KiLLeR T-LiKe (nKT-LiKe) CeLLS in CHROniC 
OBSTRUCTive PULMOnARY DiSeASe (COPD)
Natural killer T-like cells comprise a unique subgroup of lymphocytes that express features of both 
T cells and natural killer (NK) cells. NKT-like cells co-express T-cell receptors and CD4 or CD8 
(or CD4−/CD8−), together with markers associated with NK cells, such as CD56 (Figure 1C) and/
or CD16 or CD161. Acquisition of CD11b represents an early event in CD8+ T-cell differentiation, 
which may allow extravasation to peripheral tissues (1, 2). These cells are a small but important 
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FigURe 1 | Flow cytometric gating technique used to identify CD8+CD28null natural killer T-like (nKT-like) cells (and CD8+CD28+ nKT-like cells) from 
the peripheral blood of patients with chronic obstructive pulmonary disease. (A) Identification of lymphocytes as CD45+ low side scatter (SSC) events. (B) 
Removal of red blood cell contaminations removed by lymphocyte gating using forward scatter vs. SSC characteristics. (C) Identification of NKT-like cells as 
CD3+CD56+ events. (D) Identification of CD28null and CD28+ NKT-like cells using CD8 vs. CD28 staining. (e) Expression of IFNγ and histone deacetylase (HDAC)2 in 
CD8+CD28null and CD8+CD28+ cells. (F) Expression of P-glycoprotein-1 (Pgp1), glucocorticoid receptor (GCR), and heat shock protein (Hsp)90 expression in 
CD8+CD28null and CD8+CD28+ cells. Note: the majority of NKT-like cells are CD8+ and CD28null. These cells express reduced HDAC2, GCR, and Hsp90 but 
increased IFNγ compared with CD8+CD28+ NKT-like cells (Pgp1 unchanged).
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subset of lymphocytes that represent a bridge between innate and 
adaptive immunity.
There has been conflicting evidence regarding changes in 
NKT-like cell numbers in COPD. Numbers of these cells have 
been reported to be decreased in the peripheral blood of patients 
with COPD (3). One study showed numbers to be unchanged (4), 
while a third reported increased numbers (5). However, further 
characterization into CD4+ or CD8+ NKT-like cells was not 
performed in any of these reports. NKT-like cells have also been 
reported to be increased in induced sputum and bronchoalveolar 
lavage (BAL) of COPD patients and, importantly, have been 
shown to be cytotoxic to autologous lung cells (3, 4, 6).
LOSS OF CD28 On SeneSCenT 
LYMPHOCYTeS in COPD
Following persistent antigenic stimulation, NKT-like cells can 
lose co-stimulatory molecules, undergo telomere shortening, and 
exhibit defective IL-2 production; changes that define the state 
of replicative senescence. The majority of these “effector senes-
cent” lymphocytes are CD8+, CD45RA+, CD11abright, CD28null 
(Figure 1D), CD62L−, and CCR7−. Expansion of these cells are 
found in the elderly and in other clinical conditions involving 
chronic activation of the immune system such as viral infections, 
rheumatic, and autoimmune diseases (7). Increased numbers have 
also been reported in chronic inflammatory lung diseases includ-
ing COPD and in patients following lung transplantation (8, 9).
STeROiD ReSiSTAnCe in CD8+CD28null 
nKT-LiKe CeLLS in COPD
Steroid Resistant CD8+ T Cells in COPD
Patients with COPD have been shown to be resistant to the immu-
nosuppressant effects or glucocorticoids (10). Most of the investi-
gations into steroid resistance in this disease have focused on the 
role of the airway macrophages and neutrophils (10); however, 
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the mechanisms underlying steroid resistance in lymphocytes 
in patients with COPD until recently has been largely unknown. 
The role of T-cells is likely to be important in this regard, as their 
increased numbers have been reported in the lungs of patients 
with COPD. A study by Maeno et al. demonstrated an important 
requirement for CD8+ T cells in the development of cigarette 
smoke-induced emphysema. They suggested a unifying pathway 
whereby CD8+ T cells are the central regulators of the inflammation 
network in COPD (11). Inhaled corticosteroids have been shown 
to reduce exacerbation rates and improve health status in patients 
with COPD but can also increase the risk of pneumonia (12, 13). 
The numbers of bronchial CD8+ T-cells were reduced following 
long-term treatment with inhaled corticosteroids in ex-smoker 
COPD patients only but not persistent COPD smokers (12, 13).
There have been reports of increased numbers of CD8+ T cells 
in the peripheral blood, BAL, and lung parenchyma from COPD 
smoker and ex-smoker patients compared with healthy smokers 
and control subjects (14, 15). This indicates the systemic involve-
ment of these cells in COPD. The production of the pro-inflam-
matory cytokines, IFNγ and TNFα, by CD8+ T cells was increased 
from peripheral blood, BAL, and intraepithelial compartments 
in patients with COPD. This was regardless of whether patients 
were receiving inhaled corticosteroids (14) indicating the lack of 
effectiveness of steroids at reducing pro-inflammatory cytokines 
by these cells. However, further lymphocyte subtyping with 
NKT-like cell markers was not performed. Steroid resistance was 
further shown in vitro by assessing the production of IFNγ by fol-
licular CD8+ T cells in the presence of 0.1–1µM dexamethasome 
(16), although further subtyping of NKT-like subsets was not 
performed in the study. Recently, steroid resistant CD8+CD28null 
NKT-like cells were reported to be increased in number and 
to express increased levels of the cytotoxic mediators, perforin 
and granzyme b. Pro-inflammatory cytokines, IFNγ and TNFα 
(8), were also increased in the peripheral blood of patients with 
COPD, confirming the important role of these lymphocytes in 
steroid resistance.
P-glycoprotein-1 (Pgp1) in CD8+CD28null 
nKT-Like Cells
P-glycoprotein is a transmembrane efflux pump well-character-
ized in drug-resistant cancer cells (17) and also thought to play 
a role in the function of steroid resistant lymphocytes in COPD. 
Pgp1 expression has been shown to be increased in T, NKT, and 
NK cells that also co-express IFNγ, TNFα, and granzyme b, in 
peripheral blood from COPD patients compared with healthy 
controls (Figure 1). However, further differentiation of NKT-like 
cells into CD4+ and CD8+ subsets was not performed (18).
Recent further investigations by the same authors comparing 
COPD patients with healthy age-matched controls showed no 
difference in Pgp1 expression between CD8+CD28null NKT-like 
and CD28+CD8+ NKT-like subsets. However, the percentages of 
CD8+Pgp1+CD28null NKT-like and CD8+Pgp1+CD28+ NKT-like 
cells were both increased in the COPD group (8) (Figure 2A). 
Treatment with very low-dose cyclosporine A (CsA), a Pgp1 
inhibitor (2.5 ng/ml; approximately 25 times less than that used 
for transplant rejection therapy), combined with standard dose 
corticosteroid [1µM prednisolone (pred)] resulted in synergistic 
inhibition of pro-inflammatory cytokines in CD8+Pgp1+CD28null 
NKT-like cells (18) (Figure 2B). These data indicate that these 
agents may be an effective add-on therapy to standard steroid 
treatment.
Loss of glucocorticoid Receptor (gCR) in 
CD8+CD28null nKT-Like Cells in COPD
Glucocorticoids must bind to the GCR in the cytoplasm of a cell 
before being transported to the nucleus. A recent study exam-
ined the expression of GCR in pro-inflammatory NKT-like cells 
in the peripheral blood of patients with COPD (8). COPD was 
associated with increased percentage of CD28null NKT-like cells 
compared with healthy controls. Loss of CD28 was associated 
with an increase in percentage of NKT-like cells producing IFNγ 
and TNFα and importantly, with a loss of GCR (8) (Figure 2C). A 
significant loss of GCR in CD8+CD28null NKT-like cells was noted 
in both COPD patients and controls compared with CD8+CD28+ 
NKT-like cells (mean  ±  SEM: 9  ±  4% CD8+GCR+CD28null 
NKT-like cells vs. 39 ±  7% CD8+GCR+CD28+ NKT-like cells 
in COPD). There was a significant correlation between GCR 
expression and IFNγ and TNFα production by CD8+ NKT-like 
cells. Taken together, these data show a loss of GCR in senes-
cent CD8+CD28null NKT-like cells and suggest that alternate 
treatment options to glucocorticoids are required to suppress 
pro-inflammatory cytokine production in patients with COPD.
Decreased Histone Deacetylase (HDAC)2 
in CD8+CD28null nKT-Like Cells in COPD
Histone acetyltransferases and HDAC are enzymes that upregu-
late and downregulate pro-inflammatory gene transcription, 
respectively. HDAC2 is required by corticosteroids to switch off 
activated inflammatory genes and is reduced in lung macrophages 
in COPD (10). A recent study showed that HDAC2 expression 
was suppressed in pro-inflammatory CD8+CD28null NKT-like 
cells in patients with COPD (19) and negatively correlated with 
the percentage of CD8+CD28null NKT-like cells producing IFNγ 
or TNFα in all subjects (e.g., COPD: R = −0.789, p < 0.001 for 
CD8+CD28null NKT-like cells producing IFNγ) (Figure  2D). 
Theophylline is an activator of HDAC and enhances the anti-
inflammatory effects of corticosteroids in alveolar macrophages 
in COPD patients (20). Addition of theophylline has recently 
been shown to increase the anti-inflammatory effects of steroids 
in senescent lymphocytes from COPD patients (18). Addition of 
low-dose theophylline (5 mg/l) induced a synergistic upregula-
tion of HDAC2 in CD8+CD28null NKT-like cells in the presence 
of 1µM pred and 2.5 ng/ml CsA (Figure 2E). This was associ-
ated with a decrease in pro-inflammatory cytokine production 
by these cells. These findings suggest this form of therapy may 
enhance the anti-inflammatory effects of steroids and thus reduce 
inflammation caused by these cells in COPD.
Decreased Heat Shock Protein (Hsp)90 in 
CD8+CD28null nKT-Like Cells in COPD
Glucocorticoid receptor must be bound to molecular chaperones 
Hsp70 and Hsp90 to acquire a high-affinity steroid binding 
FigURe 2 | Schematic diagram summarizing reported findings in peripheral blood CD8+CD28null natural killer T-like (nKT-like) cells in chronic 
obstructive pulmonary disease (COPD). Glucocorticoids enter cells by overcoming membrane drug efflux pump P-glycoprotein-1 (Pgp1) and binding to the 
glucocorticoid receptor (GCR) in the cytoplasm. GCR must be bound to the molecular chaperones heat shock protein (Hsp)70 and Hsp90 to acquire a high-affinity 
steroid binding conformation, and traffic to the nucleus where engagement of histone deacetylases (HDACs), particularly HDAC2, results in reduction of  
pro-inflammatory gene activation. In COPD compared with age-matched healthy control subjects: (A) Pgp1+ NKT-like cells are increased in COPD, reducing 
intracellular levels of GC. Expression of GCR (C), Hsp90 (F), and HDAC2 (D) are decreased in CD8+CD28null NKT-like cells (no change in Hsp70) (g) reducing steroid 
effectiveness. (i) The percentage of steroid resistant CD8+CD28nullCD137+ NKT-like cells is increased. Possible therapeutic targeting to overcome steroid resistance 
CD8+CD28null NKT-like cells in COPD: (B) Pgp1 is synergistically decreased in the presence of 2.5 ng/ml cyclosporine A (CsA) and 1µM prednisolone (pred).  
(H) Hsp90 expression is increased in the presence of 2.5 ng/ml CsA and 1µM pred. (e) HDAC2 expression is increased in the presence of 5 mg/ml theophylline, 
2.5 ng/ml CsA, and 1µM pred. (J) Blocking CD137 expression with anti-CD137 antibody. (K) This targeting results in decreased IFNγ and TNFα pro-inflammatory 
cytokine expression.
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conformation and traffic to the nucleus (21). A recent study 
examined expression of Hsp70/90 in CD8+CD28null NKT-like 
cells from the peripheral blood of patients with COPD (22). Loss 
of expression of Hsp90 and GCR from the CD8+CD28null NKT-
like cells in COPD was noted (Figure 2F), whereas expression of 
Hsp70 was unchanged (Figure 2G). The loss of Hsp90 was shown 
to correlate with the cytotoxic/pro-inflammatory potential of 
these cells and importantly, degree of airflow limitation in patients 
with COPD. The immunosuppressant, CsA, binds to the GCR–
Hsp90 complex, but not Hsp70 (23), and was shown to upregulate 
Hsp90 with an associated decrease in pro-inflammatory cytokine 
production by CD8+CD28null NKT-like cells when combined with 
1µM pred (Figure  2H). The concentration of CsA (2.5  ng/ml) 
used in these in vitro experiments was 50 times less than that used 
for patients following lung transplant to prevent graft rejection. 
Hence, these low concentrations are not likely to be associated 
with any of the side effects reported with higher doses of this drug.
inHiBiTing CD137 eXPReSSiOn in 
CD8+CD28null nKT-LiKe CeLLS in COPD
The loss of CD28 on CD8+CD28null NKT-like cells from COPD 
subjects has been reported to be associated with an upregulation 
of the “alternate” co-stimulatory molecule CD137 (4-1BB) (24) 
(Figure  2I). Targeting CD137 has been shown to be effective 
in treatment of rheumatoid arthritis and may thus be effective 
in other diseases associated with increased expression of this 
co-stimulatory molecule, including COPD (25). In vitro stud-
ies showed that blocking CD137 with an anti-CD137 antibody 
following PHA stimulation of PBMC from COPD patients 
resulted in a decrease in the percentage of CD8+CD28null NKT-
like cells producing IFNγ, TNFα, and granzyme b production 
(26) compared with CD8+CD28+ NKT-like cells (Figure  2J), 
whereas stimulatory CD137 antibody increased production of 
these molecules. This indicates that targeting CD137 with anti-
CD137 antibody may have novel therapeutic options for reducing 
inflammation in patients with COPD.
DOeS OXiDATive STReSS PLAY A ROLe 
in STeROiD ReSiSTAnCe in nKT-LiKe 
CeLLS?
There is increasing evidence that oxidative stress is important in 
the pathogenesis of COPD (27, 28). Oxidative stress occurs due 
to an increase of reactive oxygen species (ROS) causing damage 
to lipids, proteins, and DNA. Increased burden of oxidants from 
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cigarette smoke and air pollutants and from ROS and reactive 
nitrogen species (RNS) released from inflammatory neutrophils, 
eosinophils, macrophages, and epithelial cells occurs in the lungs 
of COPD patients (27–29). The aging process is associated with 
a decrease in the antioxidant defense mechanisms in the lung 
resulting in increased ROS and RNS (30). Although there is a 
causal link between ROS, COPD, and aging in cellular senescence 
in many cells in the lung, sensitivity of individual lymphocyte 
subsets to oxidative stress and how this process affects disease 
progression remains largely unknown (30). While one study 
showed an association between ROS and cellular senescence in 
lymphocytes, some markers of oxidative stress were decreased 
(31). Increasing concentrations of ROS has been shown to sup-
press Th1 cells and increase Th2 cells, findings at odds with ours 
and many others in patients with COPD (30). Furthermore, it 
has been shown that neutrophils in the inflamed lung produce 
large amounts of ROS, which suppress T cells, while macrophages 
secrete cysteine and thioredoxin, which increase oxidation resist-
ance of T cells (32). Although oxidative stress has been shown to 
inhibit expression of GCRs in total blood leukocytes, the effect on 
T and NKT-like cells was not determined (33). It is clear further 
research is needed specifically on the effect of ROS on T cell and 
NKT-like cell biology (32).
FUTURe THeRAPY FOR COPD
Lymphocyte senescence and glucocorticoid resistance have been 
described in several other inflammatory conditions such as 
cardiovascular disease (34), autoimmune disease (35), arthritis 
(36), IBD (37) associated with aging (38), and aging with asso-
ciated inflammation in COPD (39). Some of these conditions 
are associated with respiratory muscle dysfunction resulting in 
further increases in ROS and oxidative stress (40). CD28null T cells 
have been reported in patients with asthma (41), another inflam-
matory lung disease also associated with increased ROS and 
oxidative stress (42). Interestingly, several of these inflammatory 
diseases are also comorbid conditions associated with COPD (10) 
and therefore may also be associated with increased cytotoxic/
pro-inflammatory CD8+CD28null NKT-like cells. Hence, target-
ing the pro-inflammatory nature of these cells by decreasing the 
expression of Pgp1 and/or CD137 and increasing the expression 
of GCR, HDAC2, and Hsp90 by CD8+CD28null NKT-like cells 
may reduce inflammation (Figure 2K) associated with a range 
of steroid resistant diseases including COPD and comorbid 
conditions associated with COPD. Furthermore, targeting these 
cytotoxic/pro-inflammatory cells at early onset of COPD may 
prevent the inevitable spiral of worsening lung function, and 
associated comorbidity of this progressive debilitating disease, 
and reduce the associated massive health-care costs (43).
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